Antibodies

03 Feb 2020 United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint
02 Feb 2020 Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, RUXIENCE™ (rituximab)
02 Feb 2020 Bristol-Myers Squibb Withdraws European Application of Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
30 Jan 2020 F-star Therapeutics Announces FDA Acceptance of IND Application for FS120
28 Jan 2020 FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
28 Jan 2020 Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept in Pre-Clinical Study
28 Jan 2020 Leronlimab Under Evaluation for Potential Treatment of Coronavirus
28 Jan 2020 WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus
28 Jan 2020 AbCellera Is Mobilizing a Response to the Novel Coronavirus Outbreak as Part of Its DARPA P3 Program
28 Jan 2020 Surface Oncology Announces FDA Clearance of SRF617 and SRF388 INDs to Initiate Phase 1 Clinical Trials
28 Jan 2020 Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension
27 Jan 2020 AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
27 Jan 2020 Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
27 Jan 2020 AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan
27 Jan 2020 Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
25 Jan 2020 CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
25 Jan 2020 Alpine Immune Sciences Presents New Preclinical Data at 2020 Crohn’s & Colitis Congress
24 Jan 2020 Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-Invasive Urothelial Cancer
23 Jan 2020 The European Commission Approves Expanded Use of Janssen’s STELARA® (ustekinumab) for the Treatment of Paediatric Patients With Moderate to Severe Plaque Psoriasis
23 Jan 2020 Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
22 Jan 2020 Vir Biotechnology applying multiple platforms to address public health risk from Wuhan coronavirus
22 Jan 2020 FDA Approves TEPEZZA (TM) (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
21 Jan 2020 BeiGene Announces that the Phase 3 Clinical Trial of its Anti-PD-1 Antibody Tislelizumab in Patients with First-Line Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis
21 Jan 2020 US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
21 Jan 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top